I Specimen Inc. ISPC
We take great care to ensure that the data presented and summarized in this overview for iSpecimen Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ISPC
View allLatest Institutional Activity in ISPC
Top Purchases
Top Sells
About ISPC
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Insider Transactions at ISPC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 14
2023
|
Benjamin Bielak Chief Info Officer & Secretary |
BUY
Open market or private purchase
|
Direct |
18,000
+17.59%
|
$0
$0.72 P/Share
|
|
May 31
2023
|
Tracy Curley CEO, CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
4,400
+8.16%
|
$4,400
$1.25 P/Share
|
|
Jan 17
2023
|
Jill Mullan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66,637
+21.3%
|
$66,637
$1.0 P/Share
|
|
Jan 06
2023
|
Christopher Ianelli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
845
+0.2%
|
$845
$1.0 P/Share
|
|
Jan 01
2023
|
John L Brooks Director |
BUY
Grant, award, or other acquisition
|
Direct |
125
+3.7%
|
-
|
|
Jan 01
2023
|
Joseph J. Basile Director |
BUY
Grant, award, or other acquisition
|
Direct |
63
+50.0%
|
-
|
|
Jan 01
2023
|
Christopher Ianelli Director |
BUY
Grant, award, or other acquisition
|
Direct |
92
+0.02%
|
-
|
|
Jan 01
2023
|
Jill Mullan Director |
BUY
Grant, award, or other acquisition
|
Direct |
92
+0.04%
|
-
|
|
Jan 01
2023
|
Steven R. Ph.D. Gullans Director |
BUY
Grant, award, or other acquisition
|
Direct |
125
+3.7%
|
-
|
|
Jan 01
2023
|
Andrew L. Ross Director |
BUY
Grant, award, or other acquisition
|
Direct |
125
+0.01%
|
-
|
|
Oct 24
2022
|
Christopher Ianelli Director |
SELL
Other acquisition or disposition
|
Direct |
18,229
-4.12%
|
-
|
|
Oct 24
2022
|
Jill Mullan Director |
SELL
Other acquisition or disposition
|
Direct |
18,229
-9.22%
|
-
|
|
Jun 22
2022
|
Benjamin Bielak Chief Info Officer & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,148
-4.53%
|
$6,296
$2.36 P/Share
|
|
Jun 22
2022
|
Christopher Ianelli Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,903
-0.87%
|
$7,806
$2.36 P/Share
|
|
Jun 22
2022
|
Jill Mullan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,124
-1.55%
|
$6,248
$2.36 P/Share
|
|
Jun 22
2022
|
Tracy Curley CEO, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,738
-5.72%
|
$5,476
$2.36 P/Share
|
|
Feb 23
2022
|
Christopher Ianelli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
48,106
+9.72%
|
$48,106
$1.0 P/Share
|
|
Feb 22
2022
|
Christopher Ianelli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,099
+0.77%
|
$3,099
$1.0 P/Share
|
|
Feb 22
2022
|
Jill Mullan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22,395
+5.2%
|
$22,395
$1.0 P/Share
|
|
Nov 17
2021
|
Tracy Curley CEO, CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
2,000
+16.67%
|
$10,000
$5.12 P/Share
|